Drugs / Food / Manufacturing / Therapeutics / Drug / Europe blog main / National / National blog main / New York blog main / New York top stories / San Francisco blog main / San Francisco top stories / Aimmune Therapeutics / anaphylaxis / Biotech / clinical trials / DBV Technologies / epinephrine / EpiPen / FDA / Immunotherapy / Jayson Dallas / Life Sciences / Novartis / Palforzia / peanut allergy / Pink Sheet / REMS / Ultragenyx Pharmaceutical

Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing

Posted On: Mar 24, 2020   |   Posted By: Xconomy

Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing

Aimmune Therapeutics Inc. is navigating a host of new challenges as it launches Palforzia, the first peanut allergy immunotherapy to be approved by the US Food and Drug Administration. Most notably, it must get physician practices and individual allergists certified to administer the treatment. Aimmune president and CEO Jayson Dallas talked to our sister publication the Pink Sheet about the certification process, part of the company's Risk Evaluation and Mitigation Strategy , in an interview in New York last month. He also discussed the complexities involved in manufacturing the food-derived treatment. Some analysts have speculated that the restriction...

Continue reading ...